Profil
Matthew Fearer worked as a Senior Director of Corporate Communications at Acceleron Pharma, Inc. from 2021 to 2022.
He also served as the Director of Communications & Public Affairs at the Whitehead Institute for Biomedical Research.
In 2023, he was the Vice President of Corporate Communications at Viridian Therapeutics, Inc.
Ehemalige bekannte Positionen von Matthew Fearer
Unternehmen | Position | Ende |
---|---|---|
VIRIDIAN THERAPEUTICS, INC. | Public Communications Contact | 01.12.2023 |
ACCELERON PHARMA INC. | Public Communications Contact | 01.04.2022 |
Whitehead Institute for Biomedical Research
Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Whitehead Institute for Biomedical Research provides research and technology services. Its services include biomedical, genomics, and genetics for students. The company was founded by Edwin C. Whitehead in 1982 and is headquartered in Cambridge, MA. | Public Communications Contact | 01.10.2016 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
VIRIDIAN THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Whitehead Institute for Biomedical Research
Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Whitehead Institute for Biomedical Research provides research and technology services. Its services include biomedical, genomics, and genetics for students. The company was founded by Edwin C. Whitehead in 1982 and is headquartered in Cambridge, MA. | Commercial Services |
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |